Research paper
Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial
Study answer
What this study found
Daily flaxseed-derived lignan supplementation modestly improved glycemic control by lowering HbA1c versus placebo, but it did not improve fasting glucose, insulin concentrations, insulin resistance, or lipid profiles. HbA1c changed by -0.1060.65% with lignan versus 0.0960.52% with placebo (P = 0.001). Fasting glucose, insulin, HOMA-IR, and blood lipid profiles showed no significant between-treatment differences, although HOMA-IR was reported to decrease by 3.3% from baseline during lignan treatment. Adherence was high (96% during lignan, 94% during placebo), and reported adverse events…
- Study & population
- Randomized, double-blind, placebo-controlled cross-over trial in adults with type 2 diabetes and mild hypercholesterolemia in Shanghai, China.
- Intervention
- Adults in the active arm received 360 mg/day of flaxseed-derived lignan, specifically secoisolariciresinol diglucoside (SDG), taken orally as three capsules per day for 12 weeks.
- Key limitation
- The completed sample was small, with only 34 participants analyzed in each treatment phase, which limits power and precision.
View source
Open PDFOriginal abstract
Background Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on g…